135053-20-2Relevant articles and documents
Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization
LaLonde, Judith M.,Le-Khac, Matthew,Jones, David M.,Courter, Joel R.,Park, Jongwoo,Schoen, Arne,Princiotto, Amy M.,Wu, Xueling,Mascola, John R.,Freire, Ernesto,Sodroski, Joseph,Madani, Navid,Hendrickson, Wayne A.,Smith, Amos B.
supporting information, p. 338 - 343 (2013/05/08)
The design, synthesis, thermodynamic and crystallographic characterization of a potent, broad spectrum, second-generation HIV-1 entry inhibitor that engages conserved carbonyl hydrogen bonds within gp120 has been achieved. The optimized antagonist exhibits a submicromolar binding affinity (110 nM) and inhibits viral entry of clade B and C viruses (IC50 geometric mean titer of 1.7 and 14.0 μM, respectively), without promoting CD4-independent viral entry. The thermodynamic signatures indicate a binding preference for the (R,R)- over the (S,S)-enantiomer. The crystal structure of the small-molecule/gp120 complex reveals the displacement of crystallographic water and the formation of a hydrogen bond with a backbone carbonyl of the bridging sheet. Thus, structure-based design and synthesis targeting the highly conserved and structurally characterized CD4-gp120 interface is an effective tactic to enhance the neutralization potency of small-molecule HIV-1 entry inhibitors.
CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
-
Page/Page column 76, (2013/07/05)
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gpl20, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD- 556.
Vapour-assisted enzymatic hydrolysis of β-lactams in a solvent-free system
Forro, Eniko,Fueloep, Ferenc
, p. 1005 - 1009 (2008/09/21)
A new, solvent-free, vapour-assisted method, developed for the synthesis of carbocyclic cis β-amino acid enantiomers through the Candida antarctica lipase B-catalysed enantioselective (E >200) hydrolysis of β-lactams with 0.5 equiv of H2O at 70 °C, has been demonstrated to be applicable on a preparative scale to produce (±)-2 (the starting racemate for cispentacin), (±)-3 (the starting racemate for 4-tert-butylcispentacin, a new cispentacin analogue) and (±)-7 (the starting racemate for 1,4-ethylene-bridged cispentacin).
An efficient enzymatic synthesis of benzocispentacin and its new six- and seven-membered homologues
Forro, Eniko,Fueloep, Ferenc
, p. 2587 - 2592 (2008/02/04)
A very efficient enzymatic method was developed for the synthesis of new enantiomeric benzocispentacin and its six- and seven-membered homologues through the Lipolase (lipase B from Candida antarctica) catalyzed enantioselective (E > 200) ring opening of 3,4-benzo-6-azabicyclo[3.2.0]heptan-7-one, 4,5-benzo-7-azabicyclo[4.2.0]octan-8-one, and 5,6-benzo-8-azabicyclo[5.2.0] nonan-9-one with H2O in iPr2O at 60°C. The (1R,2R)-β-amino acids (ee ≥ 96%, yields ≥ 40%) and (1S,6S)-, (1S,7S)-, and (1S,8S)-β-lactams (ee > 99%, yields ≥ 44%) produced could be easily separated. The ring opening of racemic and enantiomeric β-lactams with 18% HCl afforded the corresponding β-amino acid hydrochlorides.
